title: Cyst infections in patients with autosomal dominant polycystic kidney disease.
abstract: OBJECTIVE
  Cyst infection is a complex diagnostic and therapeutic issue in patients with autosomal dominant polycystic kidney disease (ADPKD); however, published data regarding the diagnosis and the management of cyst infections in patients with ADPKD are sparse.
  
  
  METHODS
  A retrospective study was conducted in a referral center for patients with ADPKD in Paris, France. We identified using a computerized database all patients who had ADPKD and were admitted in the nephrology department of Hôpital Necker between January 1998 and August 2008 with likely or definite renal and/or hepatic cyst infection. Medical files of all included patients were reviewed.
  
  
  RESULTS
  Among 389 identified patients with ADPKD, 33 (8.4%) had 41 episodes of cyst infection, including eight definite and 33 likely cases. The incidence of cyst infections in patients with ADPKD was 0.01 episode per patient per year. Microbiological documentation was available for 31 episodes (75%), Escherichia coli accounting for 74% of all retrieved bacterial strains. Positron emission tomography scan proved superior to ultrasound, Computed tomography scan, and magnetic resonance imaging for the detection of infected cysts. Clinical efficacy of initial antibiotic treatment was noted in 71% of episodes. Antibiotic treatment modification was more frequently required for patients who were receiving initial monotherapy compared with those who were receiving bitherapy. Large (diameter >5 cm) infected cysts frequently required drainage.
  
  
  CONCLUSIONS
  Positron emission tomography scan will probably make the diagnosis of cyst infections easier and more accurate. Antibiotic association, including a fluoroquinolone, and the drainage of large infected cysts remain the main treatment for cyst infections.
authors.affiliation: Department of Nephrology, Hôpital Necker, Paris, France.
authors.forename: Marion
authors.initials: M
authors.lastname: Sallée
authors.forename: Cédric
authors.initials: C
authors.lastname: Rafat
authors.forename: Jean-Ralph
authors.initials: JR
authors.lastname: Zahar
authors.forename: Benoît
authors.initials: B
authors.lastname: Paulmier
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Grünfeld
authors.forename: Bertrand
authors.initials: B
authors.lastname: Knebelmann
authors.forename: Fadi
authors.initials: F
authors.lastname: Fakhouri
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016208:Databases, Factual; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010297:Paris; D016891:Polycystic Kidney, Autosomal Dominant / Q000150:complications*; D049268:Positron-Emission Tomography; D011704:Pyelonephritis / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D012189:Retrospective Studies; D014552:Urinary Tract Infections / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones